Biotechnology

Lisata Therapeutics

Lisata Therapeutics released FY2026 Q1 earnings on May 11, 2026 (EST) with actual revenue of USD 0 and EPS of USD -0.5

Lisata Therapeutics released FY2025 earnings on March 12 (EST), actual revenue USD 170 K (forecast USD 0), actual EPS USD -1.9092 (forecast USD -2.325)

Lisata Therapeutics released FY2025 Q4 earnings on March 12 (EST), actual revenue USD 100K (forecast USD 0), actual EPS USD -0.3356 (forecast USD -0.74)

Lisata Therapeutics Reveals Operations Progress in Q3 Earnings Call

Lisata Therapeutics released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4862 (forecast USD -0.535)

Lisata Therapeutics released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 70K, actual EPS USD -1.5768

Lisata Therapeutics to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast EPS -0.535 USD

Lisata Therapeutics Reports Preliminary Results of Pancreatic Ductal Adenocarcinoma Clinical Trial

Lisata Therapeutics released FY2025 Semi-Annual Earnings on August 7 After-Market EST, with actual revenue of USD 70K and EPS of USD -1.0905

Lisata Therapeutics released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 70K (forecast USD 0), actual EPS USD -0.5414 (forecast USD -0.65)

Lisata Therapeutics to Release FY2025 Q2 Earnings on August 7 After-Market (EST), Forecast EPS -0.65 USD

Lisata Therapeutics Inc. Obtains New Patent Extended to 2040

Lisata Therapeutics Reports Positive Results for Certepetide in Treating Pancreatic Cancer

Lisata and GATC Partner to Accelerate Drug Development

Lisata Therapeutics Plans to Advance Clinical Trials for Opioid Use Disorder Treatment

Lisata Therapeutics Inc. to Attend the 2025 Boston International Biotechnology Conference

Lisata Therapeutics Holds Annual Shareholders' Meeting to Approve Key Proposals

Lisata Therapeutics CEO Reports Clinical Progress of Certepetide

Lisata Therapeutics released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5491 (forecast USD -0.53)

Lisata Therapeutics Announces Q1 2025 Earnings

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

LSTA

KALV

SILA

Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties concerning the sales of Sila Realty Trust, KalVista Pharmaceuticals, Thermon Group Holdings, and Lisata Therapeutics. The firm is encouraging shareholders to discuss their rights and options regarding these transactions, which may not provide fair deals compared to insiders. They offer legal assistance on a contingent fee basis, ensuring no upfront costs for shareholders.

PR Newswire

KalVista Pharma

Sila Realty Trust

Thermon

CECO Environmental

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

Lisata Therapeutics fell 15.34%; AbbVie rose 0.03%, with a transaction volume of USD 406 million; Revolution Medicines fell 1.94%, with a transaction volume of USD 343 million; Amgen fell 0.22%, with a transaction volume of USD 199 million; Gilead Sciences fell 0.89%, with a market capitalization of USD 171.9 billion

Price Alert

U.S. stock market update: Lisata Therapeutics stock price plummets 15.34%, financial update raises market concerns and increases risks

Lisata Therapeutics shares are trading higher after the company entered into a definitive agreement to be acquired by Kuva Labs.

benzinga_article

Lisata Therapeutics has entered into a definitive agreement to be acquired by Kuva Labs, Inc. Each Lisata stockholder will receive $5.00 per share in cash at closing, plus a contingent value right for an additional $1.00 per share based on future FDA approvals. The transaction, unanimously approved by Lisata's board, is expected to close in Q2 2026, after meeting customary conditions. Following the acquisition, Lisata will be delisted from Nasdaq and cease to be a reporting company under U.S. securities laws.

StockTitan

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. | LSTA Stock News

Lisata Therapeutics(LSTA.US)

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

U.S. stock market update: Lisata Therapeutics stock price plummets 15.34%, financial update raises market concerns and increases risks

Lisata Therapeutics shares are trading higher after the company entered into a definitive agreement to be acquired by Kuva Labs.

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. | LSTA Stock News